Breaking New Ground in IPF Treatment: The Synergy of Stem Cells and Metformin
Published in Bioengineering & Biotechnology, Cell & Molecular Biology, and Biomedical Research
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with limited treatment options. Traditional therapies like pirfenidone and nintedanib only slow progression, leaving a critical need for innovative approaches.
The Challenge of IPF
IPF is marked by relentless scarring of lung tissue, driven by oxidative stress, inflammation, and dysfunctional repair mechanisms. Current treatments fail to address the root causes, underscoring the urgency for new strategies.
Our Hypothesis
We hypothesized that combining the anti-fibrotic properties of metformin (an FDA-approved diabetes drug) with the regenerative and anti-inflammatory power of MSCs could synergistically:
-
Reduce collagen deposition.
-
Combat oxidative stress.
-
Modulate key fibrotic pathways (e.g., TGF-β1).
Key Findings
-
Superior Synergy: The combo therapy (MSCs + metformin) outperformed single treatments, nearly restoring normal lung structure in rats.
-
Oxidative Stress Control: It normalized biomarkers like MDA (lipid peroxidation) and catalase, indicating reduced cellular damage.
-
Gene Regulation: Downregulated pro-fibrotic (TGF-β1, IL-6) and upregulated anti-inflammatory (IL-10) genes.
-
Collagen Reduction: Masson’s trichrome staining confirmed dramatic decreases in fibrosis.
Why This Matters
-
Metformin’s safety profile and MSCs’ regenerative capacity make this combo clinically translatable.
-
The therapy targets multiple pathways—AMPK activation, TGF-β1 suppression, and immune modulation—offering a multi-pronged attack on fibrosis.
-
Unlike current drugs, this approach may reverse fibrosis, not just slow it.
https://doi.org/10.1007/s12010-025-05289-y
#IPF #StemCells #Metformin #PulmonaryFibrosis #MedicalResearch
Nourhan began her career in Egypt with a bachelor’s degree in biotechnology and a teaching role at Cairo University. Her master’s research at the National Cancer Institute focused on miRNA-124 and FOXA2 in liver cancer. In 2018, she received a DAAD scholarship to pursue a Ph.D. in Prof. Götte’s lab at University Hospital Münster, Germany, investigating syndecan-1’s role in breast cancer radioresistance, resulting in multiple publications and awards. After her Ph.D., she worked on the BIOMET4D project in Prof. Krieg’s Lab at University Hospital Cologne, researching 4D biodegradable implants for dynamic tissue restoration. She also worked on developing a 3D organoid model to study sebaceous gland biology and pathology. She is currently working as a Lecturer at Biotechnology Department, Faculty of Science, Cairo University, Egypt. She is the funder of Egyptian Women’s Academic Network in Germany (EWAN) in GESR-eV.de.
